Investigating non-inferiority or equivalence in time-to-event data under non-proportional hazards.
Equivalence
Non-inferiority
Non-proportional hazards
Survival analysis
Time-to-event data
Journal
Lifetime data analysis
ISSN: 1572-9249
Titre abrégé: Lifetime Data Anal
Pays: United States
ID NLM: 9516348
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
05
03
2022
accepted:
10
01
2023
medline:
13
6
2023
pubmed:
29
1
2023
entrez:
28
1
2023
Statut:
ppublish
Résumé
The classical approach to analyze time-to-event data, e.g. in clinical trials, is to fit Kaplan-Meier curves yielding the treatment effect as the hazard ratio between treatment groups. Afterwards, a log-rank test is commonly performed to investigate whether there is a difference in survival or, depending on additional covariates, a Cox proportional hazard model is used. However, in numerous trials these approaches fail due to the presence of non-proportional hazards, resulting in difficulties of interpreting the hazard ratio and a loss of power. When considering equivalence or non-inferiority trials, the commonly performed log-rank based tests are similarly affected by a violation of this assumption. Here we propose a parametric framework to assess equivalence or non-inferiority for survival data. We derive pointwise confidence bands for both, the hazard ratio and the difference of the survival curves. Further we propose a test procedure addressing non-inferiority and equivalence by directly comparing the survival functions at certain time points or over an entire range of time. Once the model's suitability is proven the method provides a noticeable power benefit, irrespectively of the shape of the hazard ratio. On the other hand, model selection should be carried out carefully as misspecification may cause type I error inflation in some situations. We investigate the robustness and demonstrate the advantages and disadvantages of the proposed methods by means of a simulation study. Finally, we demonstrate the validity of the methods by a clinical trial example.
Identifiants
pubmed: 36708450
doi: 10.1007/s10985-023-09589-5
pii: 10.1007/s10985-023-09589-5
pmc: PMC10258187
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-507Informations de copyright
© 2023. The Author(s).
Références
Biometrics. 2009 Dec;65(4):1279-87
pubmed: 19210731
BMC Med Res Methodol. 2019 May 16;19(1):103
pubmed: 31096924
Epidemiology. 2010 Jan;21(1):13-5
pubmed: 20010207
Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):120-7
pubmed: 19147090
Stat Methods Med Res. 2017 Feb;26(1):75-87
pubmed: 24925887
BMC Med Res Methodol. 2022 Jan 30;22(1):34
pubmed: 35094686
JAMA. 2017 Mar 28;317(12):1224-1233
pubmed: 28350928
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Stat Med. 1993 Jul 30;12(14):1353-64
pubmed: 8210831
Stat Med. 2006 May 30;25(10):1628-38
pubmed: 16639773
Biometrics. 2010 Mar;66(1):30-8
pubmed: 19397582
J Biopharm Stat. 2021 Jan 2;31(1):79-90
pubmed: 32663108
Stat Med. 2011 Aug 30;30(19):2409-21
pubmed: 21611958
Stat Med. 2003 Jan 30;22(2):169-86
pubmed: 12520555
JAMA. 1997 Nov 5;278(17):1432-6
pubmed: 9356002
Stat Med. 2018 Feb 28;37(5):722-738
pubmed: 29181854
PLoS One. 2015 Jan 23;10(1):e0116774
pubmed: 25615624
J Clin Oncol. 2014 Aug 1;32(22):2380-5
pubmed: 24982461
Biometrics. 1993 Sep;49(3):877-81
pubmed: 8241376